After closing Clario deal, Thermo Fisher raises full-year outlook

Thermo Fisher Scientific raised its full-year forecast after first-quarter results and the March 24 closing of its Clario acquisition. (ir.thermofisher.com 1) (ir.thermofisher.com 2) The company said April 23 that first-quarter revenue rose 6% to $11.01 billion for the period ended March 28, 2026. Adjusted earnings were $5.44 a share and generally accepted accounting principles earnings were $4.43 a share. (ir.thermofisher.com) Thermo Fisher lifted 2026 revenue guidance to $47.3 billion to $48.1 billion and adjusted earnings guidance to $24.64 to $25.12 a share. The company said the new range includes the Clario deal and stronger first-quarter operating performance. (ir.thermofisher.com) (finance.yahoo.com) Clario sells software and services used in clinical trials, including electronic clinical outcome assessments, cardiac safety monitoring and medical imaging. Thermo Fisher announced the acquisition in December 2025 and completed it for an initial purchase price of about $9 billion, with additional performance-based payments possible. (ir.thermofisher.com) (biospace.com) In the quarter, Clario contributed about $30 million of revenue and $0.01 of adjusted earnings per share because the deal closed four days before quarter-end. Management said the bigger effect will come over the rest of 2026 as Clario is integrated into Thermo Fisher’s pharma-services business. (fool.com) (finance.yahoo.com) The quarter was not a uniform rebound across Thermo Fisher’s businesses. Life Sciences Solutions revenue rose 13% as reported, Laboratory Products and Biopharma Services increased 7%, Analytical Instruments was flat, and Specialty Diagnostics fell 1%. (ir.thermofisher.com) Executives said pharma and biotech demand stayed strong, bioproduction continued to grow, and clinical research pipelines improved. They also said U.S. academic and government markets remained soft. (money.usnews.com) (finance.yahoo.com) Chairman and Chief Executive Marc Casper said on the earnings call that Clario expands Thermo Fisher’s role in clinical development, where drugmakers use outside vendors to collect and analyze trial data. That pushes the company further into software and data services tied to pharmaceutical research spending. (finance.yahoo.com) (ir.thermofisher.com) Thermo Fisher also flagged inflation risk tied to the war in the Middle East, even as it raised guidance. The company’s update showed enough momentum from pharma, biotech and the new Clario business to offset weaker academic demand and a choppier macro backdrop. (marketwatch.com) (money.usnews.com)